Is TRDA or GERN more profitable?

Geron has a net margin of -34.17% compared to Entrada Therapeutics' net margin of -3,537.73%. Geron's return on equity of -24.48% beat Entrada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entrada Therapeutics -3,537.73% -57.61% -46.54% Geron -34.17% -24.48% -10.30%

Entrada Therapeutics (TRDA) Competitors

$5.67 +0.14 (+2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$5.66 0.00 (-0.09%)

As of 07:30 PM Eastern

Compare

TRDA vs. ANNX, AVTX, CADL, GERN, and DSGN

Should you buy Entrada Therapeutics stock or one of its competitors? Entrada Therapeutics's main competitors and comparable companies include Annexon (ANNX), Avalo Therapeutics (AVTX), Candel Therapeutics (CADL), Geron (GERN), and Design Therapeutics (DSGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entrada Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Annexon has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

In the previous week, Annexon and Annexon both had 1 articles in the media. Annexon's average media sentiment score of 0.00 equaled Entrada Therapeutics'average media sentiment score.

Company	Overall Sentiment
Annexon	Neutral
Entrada Therapeutics	Neutral

Annexon has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Annexon presently has a consensus price target of $15.29, suggesting a potential upside of 280.24%. Entrada Therapeutics has a consensus price target of $17.75, suggesting a potential upside of 213.05%. Given Annexon's higher possible upside, research analysts plainly believe Annexon is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

86.4% of Entrada Therapeutics shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Entrada Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Entrada Therapeutics	$25.42M	8.69	-$143.75M	-$3.96	N/A

Summary

Entrada Therapeutics beats Annexon on 7 of the 13 factors compared between the two stocks.

How does Entrada Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Avalo Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

In the previous week, Avalo Therapeutics had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 2 mentions for Avalo Therapeutics and 1 mentions for Entrada Therapeutics. Avalo Therapeutics' average media sentiment score of 0.75 beat Entrada Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Avalo Therapeutics	Positive
Entrada Therapeutics	Neutral

Avalo Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Avalo Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	12,200.83	-$78.26M	-$4.37	N/A
Entrada Therapeutics	$25.42M	8.69	-$143.75M	-$3.96	N/A

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 230.40%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 213.05%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Avalo Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Avalo Therapeutics beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Candel Therapeutics has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

Candel Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Entrada Therapeutics	$25.42M	8.69	-$143.75M	-$3.96	N/A

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Candel Therapeutics had 4 more articles in the media than Entrada Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 1 mentions for Entrada Therapeutics. Candel Therapeutics' average media sentiment score of 0.20 beat Entrada Therapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Candel Therapeutics	Neutral
Entrada Therapeutics	Neutral

Candel Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Candel Therapeutics currently has a consensus target price of $20.14, suggesting a potential upside of 102.64%. Entrada Therapeutics has a consensus target price of $17.75, suggesting a potential upside of 213.05%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Candel Therapeutics beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Geron?

Entrada Therapeutics (NASDAQ:TRDA) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Entrada Therapeutics presently has a consensus target price of $17.75, indicating a potential upside of 213.05%. Geron has a consensus target price of $4.00, indicating a potential upside of 226.53%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Entrada Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Geron has higher revenue and earnings than Entrada Therapeutics. Geron is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	8.69	-$143.75M	-$3.96	N/A
Geron	$183.88M	4.28	-$83.50M	-$0.11	N/A

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 1 articles in the media. Geron's average media sentiment score of 0.76 beat Entrada Therapeutics' score of 0.00 indicating that Geron is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
Geron	Positive

Geron has a net margin of -34.17% compared to Entrada Therapeutics' net margin of -3,537.73%. Geron's return on equity of -24.48% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Geron	-34.17%	-24.48%	-10.30%

Summary

Geron beats Entrada Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Design Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Design Therapeutics' return on equity of -34.03% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Design Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Design Therapeutics presently has a consensus price target of $17.86, suggesting a potential upside of 53.28%. Entrada Therapeutics has a consensus price target of $17.75, suggesting a potential upside of 213.05%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Design Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Entrada Therapeutics	$25.42M	8.69	-$143.75M	-$3.96	N/A

In the previous week, Design Therapeutics had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 4 mentions for Design Therapeutics and 1 mentions for Entrada Therapeutics. Design Therapeutics' average media sentiment score of 0.64 beat Entrada Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Design Therapeutics	Positive
Entrada Therapeutics	Neutral

Summary

Design Therapeutics beats Entrada Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$220.79M	$3.90B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-1.43	13.55	274.76	26.18
Price / Sales	8.69	1,283.29	632.15	98.25
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	0.71	17.17	11.21	6.34
Net Income	-$143.75M	-$22.69M	$3.50B	$381.90M
7 Day Performance	5.39%	-1.20%	-0.84%	-1.39%
1 Month Performance	-20.25%	-9.68%	-5.42%	-4.31%
1 Year Performance	-16.49%	10.09%	4.38%	-0.35%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
TRDA Entrada Therapeutics	2.2264 of 5 stars	$5.67 +2.5%	$17.75 +213.1%	-10.2%	$220.79M	$25.42M	N/A	152
ANNX Annexon	3.2918 of 5 stars	$4.03 -4.0%	$15.29 +279.3%	+27.0%	$796.23M	N/A	N/A	92
AVTX Avalo Therapeutics	3.0619 of 5 stars	$13.59 -6.9%	$45.10 +231.9%	-5.6%	$783.00M	$59K	N/A	33
CADL Candel Therapeutics	2.6812 of 5 stars	$9.87 -3.5%	$20.14 +104.1%	+53.3%	$782.79M	N/A	N/A	55
GERN Geron	2.5375 of 5 stars	$1.21 flat	$4.00 +230.6%	-11.6%	$777.39M	$204.56M	N/A	258

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ANNX, AVTX, CADL, GERN, and DSGN

How does Entrada Therapeutics compare to Annexon?

Summary

How does Entrada Therapeutics compare to Avalo Therapeutics?

Summary

How does Entrada Therapeutics compare to Candel Therapeutics?

Summary

How does Entrada Therapeutics compare to Geron?

Summary

How does Entrada Therapeutics compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ANNX, AVTX, CADL, GERN, and DSGN

How does Entrada Therapeutics compare to Annexon?

Is ANNX or TRDA more profitable?

Does the media refer more to ANNX or TRDA?

Which has more volatility and risk, ANNX or TRDA?

Do analysts rate ANNX or TRDA?

Do institutionals & insiders have more ownership in ANNX or TRDA?

Which has higher valuation and earnings, ANNX or TRDA?

Summary

How does Entrada Therapeutics compare to Avalo Therapeutics?

Is AVTX or TRDA more profitable?

Does the media refer more to AVTX or TRDA?

Which has more volatility & risk, AVTX or TRDA?

Do insiders and institutionals have more ownership in AVTX or TRDA?

Which has stronger valuation and earnings, AVTX or TRDA?

Do analysts recommend AVTX or TRDA?

Summary

How does Entrada Therapeutics compare to Candel Therapeutics?

Which has more volatility and risk, CADL or TRDA?

Which has better earnings and valuation, CADL or TRDA?

Do insiders & institutionals hold more shares of CADL or TRDA?

Does the media prefer CADL or TRDA?

Is CADL or TRDA more profitable?

Do analysts recommend CADL or TRDA?

Summary

How does Entrada Therapeutics compare to Geron?

Do analysts recommend TRDA or GERN?

Which has more risk & volatility, TRDA or GERN?

Which has preferable valuation and earnings, TRDA or GERN?

Do insiders and institutionals believe in TRDA or GERN?

Does the media prefer TRDA or GERN?

Is TRDA or GERN more profitable?

Summary

How does Entrada Therapeutics compare to Design Therapeutics?

Is DSGN or TRDA more profitable?

Do insiders & institutionals hold more shares of DSGN or TRDA?

Which has more risk & volatility, DSGN or TRDA?

Do analysts rate DSGN or TRDA?

Which has preferable earnings and valuation, DSGN or TRDA?

Does the media refer more to DSGN or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools